
MicroPort Scientific Corp.
0853.HKHKSEHealthcareMedical - Devices
Latest quote
HK$6.28
−HK$0.31 · -4.70%
0853.HK company overview
Regular session · HKT · Market data may be delayed.
Company profile
Company websiteMicroPort Scientific Corp. is an investment holding company, which engages in the research and development, manufacture, and distribution of medical devices. It operates through the following segments: Cardiovascular Devices Business, Orthopedics Devices Business, Cardiac Rhythm Management Business, Endovascular and Peripheral Vascular Devices Business, Neurovascular Devices Business, Surgical Devices Business, Heart Valve Business, Surgical Robot Devices Business, and Others. The Cardiovascular Devices Business segment offers integrated medical solutions for the treatment of coronary artery-related diseases, develops, manufactures, and commercializes coronary stents and related delivery systems, along with balloon catheters, passive accessories and active devices, in fulfilling the overall demands of doctors and patients worldwide. The Orthopedics Devices Business segment is involved in the total solutions for the treatment of orthopedic problems, with an extensive range of orthopedics products that include reconstructive joints, spine and trauma products, and other professional implants and instruments. The Cardiac Rhythm Management Business segment develops, manufactures, and markets of products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure, with products covering pacemakers, defibrillators, and cardiac resynchronization therapy devices. The Endovascular and Peripheral Vascular Devices Business segment focuses on providing integrated disease solutions for aortic and peripheral vascular diseases such as thoracic and abdominal aortic aneurysm, aortic dissection, atherosclerosis, and lower extremity arteriosclerotic occlusion. The Neurovascular Devices Business segment specializes in providing total solutions for the treatment of neurovascular diseases, including hemorrhagic stroke, cerebral atherosclerotic stenosis, and acute ischemic stroke, continuously focused on research and development, production and commercialization of neurovascular therapeutic and access devices. The Surgical Devices Business segment provides overall solutions for cardiac surgery and emergency life support. The Heart Valve Business segment includes sale, manufacture, research, and development of heart valve devices. The Surgical Robot Devices Business segment designs, develops, and commercializes innovative surgical robots. The company was founded by Zhao Hua Chang in 1998 and is headquartered in Shanghai, China.
- Industry
- Medical - Devices
- Sector
- Healthcare
- Headquarters
- CN
- CEO
- Jonathan W. Chen
- Listed since
- Sep 24, 2010
- Employees
- 6,547
Market position
Day range
Current HK$6.28
52-week range
Current HK$6.28
- Open
- HK$6.505
- Previous close
- HK$6.59
- Volume
- 8.34M
- 0.67× average
- Average volume
- 12.47M
- Average daily volume
- Market cap
- 12.01B HKD
- Beta
- 0.36
- Market reference 1
- 50-day average
- HK$6.6843
- -6.05% below average
- 200-day average
- HK$9.2479
- -32.09% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 3.52B USD
- P/E (TTM)
- 32.31×
- P/B (TTM)
- 1.35×
- P/S (TTM)
- 1.54×
- EV / EBITDA
- 39.63×
- Earnings yield
- 1.87%
- Free cash flow yield
- -2.99%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 55.18%
- Operating margin
- -3.73%
- Net margin
- 4.89%
- Return on equity
- 4.95%
- Return on assets
- 1.31%
- Return on invested capital
- -1.65%
Financial health
- Debt / equity
- 1.63×
- Current ratio
- 1.45×
- Altman Z-score
- 0.41
- Piotroski F-score
- 4 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 996.38M USD | 1.03B USD | 950.73M USD | 840.83M USD | 778.64M USD |
| Cost of goods sold | 442.05M USD | 456.97M USD | 418.63M USD | 339.06M USD | 286.87M USD |
| Gross profit | 554.33M USD | 574.09M USD | 532.1M USD | 501.77M USD | 491.77M USD |
| Research and development | 135.7M USD | 216.52M USD | 379.43M USD | 431.02M USD | 297.78M USD |
| Selling, general, and administrative | 465.65M USD | 484.68M USD | 540.73M USD | 575.76M USD | 560.49M USD |
| Operating expenses | 608.1M USD | 702.67M USD | 1.05B USD | 1.01B USD | 831.02M USD |
| Interest income | 14.6M USD | 22.75M USD | 29.4M USD | 19.11M USD | 15.83M USD |
| Interest expense | 111.43M USD | 102.24M USD | 92.73M USD | 73.91M USD | 42.71M USD |
| Depreciation and amortization | 141.78M USD | 93.43M USD | 151.25M USD | 76.31M USD | 57.46M USD |
| Operating income | −52.95M USD | −128.58M USD | −516.17M USD | −506.57M USD | −293.62M USD |
| Net income | 48.59M USD | −214.04M USD | −477.63M USD | −436.52M USD | −276.48M USD |
Company facts updated Aug 24, 2026.
Corporate actions
Annual dividends per share
Cash distributions grouped by calendar year; partial years are marked.
HK$0.043
2021 complete year+126.3% since 2017
HK$0.019
2,017
HK$0.025
2,018
HK$0.029
2,019
HK$0.053
2,020
HK$0.043
2,021
Corporate action history
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jun 28, 2021 | HK$0.043Annual | Jun 29, 2021 | Aug 18, 2021 |
Dividend | Jun 22, 2020 | HK$0.053Annual | Jun 23, 2020 | Aug 17, 2020 |
Dividend | Jun 17, 2019 | HK$0.029Annual | Jun 18, 2019 | Aug 15, 2019 |
Dividend | May 16, 2018 | HK$0.025Annual | May 17, 2018 | Aug 15, 2018 |
Dividend | Jun 22, 2017 | HK$0.019Annual | Jun 23, 2017 | Aug 15, 2017 |
Dividend | Jun 28, 2013 | HK$0.08Annual | — | — |
Ex-dividend Jun 28, 2021
HK$0.043
Annual
Record Jun 29, 2021 · Payment Aug 18, 2021
Ex-dividend Jun 22, 2020
HK$0.053
Annual
Record Jun 23, 2020 · Payment Aug 17, 2020
Ex-dividend Jun 17, 2019
HK$0.029
Annual
Record Jun 18, 2019 · Payment Aug 15, 2019
Ex-dividend May 16, 2018
HK$0.025
Annual
Record May 17, 2018 · Payment Aug 15, 2018
Ex-dividend Jun 22, 2017
HK$0.019
Annual
Record Jun 23, 2017 · Payment Aug 15, 2017
Ex-dividend Jun 28, 2013
HK$0.08
Annual
0853.HK peers
ETFs holding 0853.HK
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Total International Stock ETFVXUS13.45M0.00%646.2B USD0.05%$87.71+0.78%
Vanguard FTSE Emerging Markets ETFVWO13.37M0.01%162.3B USD0.06%$60.45+0.72%
iShares Core MSCI Emerging Markets ETFIEMG9.66M0.01%160B USD0.09%$81.57+0.64%
Vanguard FTSE All-World ex-US ETFVEU2.1M0.00%95.9B USD0.04%$85.69+0.82%
iShares Core MSCI Total International Stock ETFIXUS1.5M0.00%60.91B USD0.07%$97.945+0.76%
Schwab Emerging Markets Equity ETFSCHE1.14M0.01%12.89B USD0.06%$36.97+0.71%
State Street SPDR Portfolio Emerging Markets ETFSPEM824.34K0.00%17.57B USD0.07%$52.38+0.61%
Vanguard Total World Stock ETFVT774.75K0.00%97.9B USD0.06%$160.77+0.53%
Vanguard Total International Stock ETFVXUS- Market value
- 13.45M
- Weight
- 0.00%
- AUM
- 646.2B USD
- Expense ratio
- 0.05%
- Price / 1D
- $87.71+0.78%
Vanguard FTSE Emerging Markets ETFVWO- Market value
- 13.37M
- Weight
- 0.01%
- AUM
- 162.3B USD
- Expense ratio
- 0.06%
- Price / 1D
- $60.45+0.72%
iShares Core MSCI Emerging Markets ETFIEMG- Market value
- 9.66M
- Weight
- 0.01%
- AUM
- 160B USD
- Expense ratio
- 0.09%
- Price / 1D
- $81.57+0.64%
Vanguard FTSE All-World ex-US ETFVEU- Market value
- 2.1M
- Weight
- 0.00%
- AUM
- 95.9B USD
- Expense ratio
- 0.04%
- Price / 1D
- $85.69+0.82%
iShares Core MSCI Total International Stock ETFIXUS- Market value
- 1.5M
- Weight
- 0.00%
- AUM
- 60.91B USD
- Expense ratio
- 0.07%
- Price / 1D
- $97.945+0.76%
Schwab Emerging Markets Equity ETFSCHE- Market value
- 1.14M
- Weight
- 0.01%
- AUM
- 12.89B USD
- Expense ratio
- 0.06%
- Price / 1D
- $36.97+0.71%
State Street SPDR Portfolio Emerging Markets ETFSPEM- Market value
- 824.34K
- Weight
- 0.00%
- AUM
- 17.57B USD
- Expense ratio
- 0.07%
- Price / 1D
- $52.38+0.61%
Vanguard Total World Stock ETFVT- Market value
- 774.75K
- Weight
- 0.00%
- AUM
- 97.9B USD
- Expense ratio
- 0.06%
- Price / 1D
- $160.77+0.53%
Continue in GoAI
Research 0853.HKresearch.disclaimer





